Latest Healthcare News

Prescient Therapeutics has bolstered its cash reserves to $12.3 million following a $9.8 million capital raise, while progressing its PTX-100 cancer therapy through global Phase 2 trials with encouraging early lymphoma results.

Medical Developments International reported a strong start to FY26 with significant revenue growth driven by increased Penthrox volumes and pricing improvements in Australia, alongside steady European demand and progress on paediatric label approvals.

Orthocell Limited has reported a record $3 million quarterly revenue, driven by strong sales of its nerve repair product Remplir in Australia and Singapore, while advancing its rollout in the US and Canada ahead of schedule.

Beam Dental Bidco Pty Ltd has launched an unconditional $2.20 per share takeover bid for Pacific Smiles Group Limited, offering a 37.5% premium and aiming to consolidate full ownership. The offer is unanimously recommended by Pacific Smiles’ Independent Board Committee, with plans to delist the company from the ASX upon success.

Pacific Smiles Group has agreed to an unconditional $2.20 per share cash takeover offer from its majority shareholder Genesis Bidco, representing a 37.5% premium. The Independent Board Committee recommends shareholders accept the offer, pending no superior proposal and ongoing fairness confirmation.

MedAdvisor Limited will have its trading suspension lifted on 10 October 2025 following the lodgement of its annual financial report, marking a key moment for investors.

Pathkey.AI’s TrialKey platform continues to validate its AI-driven clinical trial success predictions, with September 2025 seeing an average 43.6% share price increase across flagged biotech stocks.

Immutep Limited has enrolled over 170 patients in its global Phase III TACTI-004 trial for advanced non-small cell lung cancer, surpassing the threshold needed for a futility analysis expected in early 2026.

PainChek Limited has achieved a landmark FDA De Novo classification for its PainChek Adult App, positioning it as the first regulated medical device for pain assessment in the US aged care sector and opening a $100 million annual market opportunity.

Anatara Lifesciences has completed the first tranche of its two-part share placement, issuing over 33 million ordinary shares to professional investors. This move marks a significant step in the company’s capital raising efforts amid ongoing product development.

Neurotech International has secured a key FDA designation for its lead drug NTI164, advancing its potential to treat Rett syndrome with regulatory and financial benefits.

Pro Medicus Limited’s European arm, Visage Imaging, has landed a significant five-year, A$10 million contract to supply next-generation imaging technology to University Hospital Heidelberg and the German Cancer Research Institute, marking a strategic expansion in Europe.